

To: Purdue Field Sales
From: Managed Markets Marketing
Bulletin Number: 212
Date: 11/03/16



FAVORABLE CHANGE

IMPORTANT FORMULARY UPDATE FOR HYSINGLA® ER

Effective: 1/1/17

As of January 1, 2017, Hysingla® ER will be unrestricted preferred on all of Cigna's commercial formularies at the lowest brand co-pay. More than 6 million commercial lives will now have Hysingla ER available at the preferred brand co-pay of approximately \$30. Previously, Cigna had Hysingla ER in a non-preferred position with a double step edit.

In addition to Hysingla ER, OxyContin and Xtampza ER will also be unrestricted preferred. All other branded opioids will be subject to a double step edit that requires trial and failure of 2 preferred agents (generic or brand) prior to adjudication.

Your Regional Account Executive will set up additional District conference calls to provide access messaging, business insights and to build out your pull-through action plans.

As always, contact your District Business Manager or Regional Account Executive with questions.

Hysingla® ER Unrestricted Preferred for Cigna Commercial

Please review the overall formulary status for Hysingla® ER to consider during your conversations with healthcare providers. Remember to use your Dynamic Access Messaging customized formulary grids and to remind the healthcare providers that inclusion on formulary does not imply superior clinical efficacy or safety.

To: Purdue Field Sales
From: Managed Markets Marketing
Bulletin Number: 212
Date: 11/03/16



FAVORABLE CHANGE

Plan, Benefit Design, and Formulary	Cigna Commercial formulary for Hysingla® ER
Tier	Preferred Unrestricted
Co-pay Amount	~\$30
Prior Authorization	NA
Quantity Limit	30 tabs per month/1 tab per day
Step Therapy	NA
Limitations	NA
Grandfathering	NA
Prescriber Specialty	NA
Authorization Period	NA
Criteria to Bypass Restriction(s)	NA
Other	NA

If you have immediate questions, please contact your manager or your Regional Account Executive.